JNJ - Johnson & Johnson

NYSE - NYSE Delayed Price. Currency in USD
129.11
+4.42 (+3.54%)
At close: 4:00PM EDT

129.02 -0.13 (-0.10%)
Pre-Market: 7:00AM EDT

Stock chart is not supported by your current browser
Previous Close124.69
Open128.53
Bid128.98 x 1800
Ask129.43 x 800
Day's Range127.56 - 130.54
52 Week Range118.62 - 148.32
Volume12,858,746
Avg. Volume6,625,858
Market Cap346.292B
Beta0.54
PE Ratio (TTM)285.64
EPS (TTM)0.45
Earnings DateOct 16, 2018
Forward Dividend & Yield3.60 (2.86%)
Ex-Dividend Date2018-05-25
1y Target Est141.95
Trade prices are not sourced from all markets
  • J&J (JNJ) Faces $4.69 Billion Verdict in Talc Case (Revised)
    Zacks3 hours ago

    J&J (JNJ) Faces $4.69 Billion Verdict in Talc Case (Revised)

    A Missouri jury asked Johnson & Johnson (JNJ) to pay $4.69 billion in damages to 22 women and their families, who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.

  • Asian stocks rise as solid US performance lifts spirits
    Associated Press7 hours ago

    Asian stocks rise as solid US performance lifts spirits

    SINGAPORE (AP) — Asian markets climbed higher on Wednesday as a sweep of positive news from Wall Street and beyond boosted confidence in the U.S. economy.

  • The Wall Street Journal8 hours ago

    [$$] Johnson & Johnson’s Pharma Business Fuels Sales Growth

    Strong sales of Johnson & Johnson’s cancer drugs and other medicines helped boost the company’s revenue and earnings for the latest quarter, but the health-products giant’s U.S. consumer business continued to struggle. Sales in the pharmaceuticals unit rose 19.9% globally, the largest increase among J&J segments. Cancer-drug sales rose 42.2%, helped by big gains for the Zytiga prostate-cancer drug and Darzalex, a blood-cancer treatment. J&J’s pharmaceutical sales topped analysts’ expectations despite what executives said was a continued decline in average net U.S. pricing after discounts and rebates.

  • Novartis (NVS) Stock Flat Ahead of Earnings: What To Watch
    Zacks9 hours ago

    Novartis (NVS) Stock Flat Ahead of Earnings: What To Watch

    Shares of Novartis (NVS) added just 0.14% during regular hours Tuesday, the last day of trading before the pharma giant releases its latest quarterly earnings report. Here's what to expect tomorrow morning.

  • What's Behind Johnson & Johnson's Double-Digit Growth?
    Motley Fool10 hours ago

    What's Behind Johnson & Johnson's Double-Digit Growth?

    Currency and acquisition tailwinds aside, the company has a slate of fast-growing drugs in its quiver.

  • TheStreet.com12 hours ago

    Jim Cramer: A Pretty Wild Rally In Three Oppositional Groups

    You combine a Fed Chairman who doesn't want to throw us into a recession, which has suddenly become a big worry, with the absence of negative trade news and you get a pretty wild rally in not two but three oppositional groups, something that's not supposed to be happening and historically almost never does. First, let's take the camp that says forget what the Fed says about economic growth, the Treasury yield curve is almost inverted and that means a recession must occur.

  • British pharma company Eusa set to unveil deal with giant Johnson & Johnson
    The Telegraph13 hours ago

    British pharma company Eusa set to unveil deal with giant Johnson & Johnson

    British pharma company Eusa set to unveil deal with giant Johnson & Johnson

  • What Happened in the Stock Market Today
    Motley Fool14 hours ago

    What Happened in the Stock Market Today

    On a day stocks climbed following optimistic comments by the chairman of the Federal Reserve, Netflix reported disappointing subscriber additions, and Johnson & Johnson rose on strong pharmaceuticals sales.

  • Barrons.com14 hours ago

    After the Bell: Dow Rises 56 Points as Stocks Keep Chugging Higher

    Stocks notched another day of gains on Tuesday, on a day when there was little in the way of market-moving news. The Dow Jones Industrial Average gained 55.53 points, or 0.22%, to 25,119.89, while the S&P 500 is up 11.12 points, or 0.40%, to 2809.55 and the Nasdaq Composite added 49.40 points, or 0.63%, to 7855.12. Part of it may have been a "no news is good news," sort of mentality, as Federal Reserve Chief Jerome Powell's dry testimony before the Senate Banking Committee seemed to indicate that the Central Bank was committed to staying the course and markets largely shrugged off earnings reports on a relatively quiet day.

  • Thomson Reuters StreetEvents14 hours ago

    Edited Transcript of JNJ earnings conference call or presentation 17-Jul-18 12:30pm GMT

    Q2 2018 Johnson & Johnson Earnings Call

  • Moody's14 hours ago

    MedPlast Holdings, Inc. -- Moody's assigns B2 CFR to MedPlast Holdings, Inc.

    Rating Action: Moody's assigns B2 CFR to MedPlast Holdings, Inc. New York, July 17, 2018 -- Moody's Investors Service ("Moody's) assigned a B2 Corporate Family Rating (CFR) and B2-PD Probability of Default Rating to MedPlast Holdings, Inc. ("MedPlast"). Moody's also assigned a B1 rating to the company's first lien credit facilities comprised of a $70 million revolving credit facility and a $500 million first lien term loan and a Caa1 rating to the company's $225 million second lien term loan.

  • Associated Press14 hours ago

    Johnson & Johnson climbs while Netflix and UnitedHealth slip

    Stocks that moved substantially or traded heavily Tuesday: Netflix Inc., down $21 to $379.48 The streaming video company's second-quarter subscriber gains were weaker than analysts expected. Johnson & ...

  • EARNINGS: Johnson & Johnson stock jumps after beating on profits, trimming guidance
    Yahoo Finance Video21 hours ago

    EARNINGS: Johnson & Johnson stock jumps after beating on profits, trimming guidance

    Yahoo Finance's Alexis Christoforous and Jared Blikre break down the latest market action after Johnson & Johnson reports second quarter adjusted earnings per share that beat Wall Street expectations.

  • US companies are shipping goods before they're hit with tariffs: report
    Fox Business Videos14 hours ago

    US companies are shipping goods before they're hit with tariffs: report

    Burke Financial Strategies CEO John Burke on the reports that some U.S. companies are shipping goods overseas before they have to start paying tariffs. Burke also discussed how stocks have lagged behind earnings.